Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium hyaluronate + lidocaine is a cross-linked hyaluronic acid (HA) gel combined with lidocaine, developed by Haohai Healthcare Holdings for aesthetic soft tissue augmentation. The product functions as a dermal filler, where the sodium hyaluronate component acts as a volumizing scaffold within the extracellular matrix to correct wrinkles, folds, or volume loss. The inclusion of lidocaine, a local anesthetic, serves to block voltage-gated sodium channels, thereby reducing pain and discomfort associated with the injection process. Haohai markets these products under brands such as Matrifill and has developed multiple generations of the formulation, with approvals granted for aesthetic indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium hyaluronate + lidocaine (4269c9).